SVB Securities analyst Mani Foroohar maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report) today and set a price target of $28.00. The company’s shares closed last Thursday at $9.42, close to its 52-week low of $9.06.
According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -26.1% and a 31.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and Rocket Pharmaceuticals.
4D Molecular Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.
The company has a one-year high of $36.14 and a one-year low of $9.06. Currently, 4D Molecular Therapeutics has an average volume of 198.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
Read More on FDMT:
- SVB Securities Thinks iTeos Therapeutics’ Stock is Going to Recover
- Jasper Therapeutics (JSPR) Gets a Buy Rating from Credit Suisse
- Chardan Capital Sticks to Its Buy Rating for Vincera Pharma (VINC)
- KeyBanc Maintains a Buy Rating on indie Semiconductor (INDI)
- Exagen (XGN) Gets a Buy Rating from KeyBanc